Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

Horsham: Johnson and Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to ...